on providing unique biodegradable implants with sustained drug delivery to improve patient outcomes and quality of life for patients suffering from ophthalmic diseases such as glaucoma.
The versatile Prezia Sustained Drug Delivery Technology platform is based on extensive scientific research that has resulted in the creation of a unique method for precise and controlled drug delivery.
PolyActiva has announced the next important milestone of our transformational growth – the appointment of seasoned biopharmaceutical executive, Jerry St. Peter, as CEO and Board Director of PolyActiva, following the successful close of our $40M AUD ($25M USD) Series C financing.
PolyActiva has recently secured $40 million (AUD) in Series C funding, led by the Australian National Reconstruction Fund (NRFC), and Australia’s leading biotech investor, Brandon Capital.
The funds will support the continued clinical advancement of PolyActiva’s lead ocular implant, PA5108, as it progresses to Series 2b clinical trials in the US. In addition to advancing PA5108, PolyActiva plans to use these funds to broaden their pipeline and explore new therapeutic opportunities enabled by its proprietary PREZIA™ platform technology.
If you are interested in getting in touch with PolyActiva and wish to connect, please complete the form below:
© 2025 PolyActiva. All Rights Reserved. Caution: PolyActiva products are not for sale in the US